"Cholic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholanic acid family of bile acids in man, usually conjugated with glycine or taurine. They act as detergents to solubilize fats for intestinal absorption, are reabsorbed by the small intestine, and are used as cholagogues and choleretics.
| Descriptor ID |
D002793
|
| MeSH Number(s) |
D04.210.500.105.225 D04.210.500.221.430
|
| Concept/Terms |
Cholic Acids- Cholic Acids
- Acids, Cholic
- Cholalic Acids
- Acids, Cholalic
|
Below are MeSH descriptors whose meaning is more general than "Cholic Acids".
Below are MeSH descriptors whose meaning is more specific than "Cholic Acids".
This graph shows the total number of publications written about "Cholic Acids" by people in this website by year, and whether "Cholic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholic Acids" by people in Profiles.
-
Bile Acids and Microbiome Among Individuals With Irritable Bowel Syndrome and Healthy Volunteers. Biol Res Nurs. 2021 01; 23(1):65-74.
-
The 'in vivo lifestyle' of bile acid 7a-dehydroxylating bacteria: comparative genomics, metatranscriptomic, and bile acid metabolomics analysis of a defined microbial community in gnotobiotic mice. Gut Microbes. 2020 05 03; 11(3):381-404.
-
TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice. Cardiovasc Ther. 2018 Oct; 36(5):e12462.
-
Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
-
Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon a2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol. 2016 11; 23(12):4110-4114.
-
Liver Transplantation for HoFH in Children: Single Center Experience. Congenit Heart Dis. 2015 Nov-Dec; 10(6):520-8.
-
Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNa/Syn3 treatment in a phase l study. Cancer Gene Ther. 2014 Mar; 21(3):91-4.
-
Phase I trial of intravesical recombinant adenovirus mediated interferon-a2b formulated in Syn3 for Bacillus Calmette-Gu?rin failures in nonmuscle invasive bladder cancer. J Urol. 2013 Sep; 190(3):850-6.
-
Increased cholesterol 7alpha-hydroxylase expression and size of the bile acid pool in the lactating rat. Am J Physiol Gastrointest Liver Physiol. 2008 Apr; 294(4):G1009-16.
-
Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther. 2006 Feb; 13(2):125-30.